title: [The multimodal strategy for the neuroprotection in stroke: results of the Russian multicenter clinical-epidemiological program SOKOL].
abstract: A search for approaches to treatment of cerebrovascular diseases is urgent due to high prevalence and severity of this pathology. The objectives of the program were to analyze epidemiological indicators, risk factors, treatment patterns of chronic brain ischemia developed in patients with arterial hypertension (AH), to specify the scheme of treatment of patients with ischemic stroke (IS) with cavinton and cavinton forte and to evaluate the advantages of this drug in the complex schemes of standard therapy. An open comparison randomized multicenter prospective study included 661 patients, aged from 30 to 70 years, from 29 cities and 12 regions of the Russian Federation. Inpatients of the main group (n=344 or 52%) with II in the acute stage (5-14 days) received standard treatment with the addition of cavinton in infusions and then in tablets (cavinton forte). Patients of the comparison group received standard treatment without cavinton. The significant improvement by all indicators of efficacy was identified in both groups though positive changes were greater in the main group of patients. It is concluded that infusions of cavinton in the acute stage of IS with the following long-term treatment with tablets improve the restoration of neurological functions in the remote period compared to standard therapy.
authors: G R
authors: GR
authors: Tabeeva
authors: Iu E
authors: IuE
authors: Azimova
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D019610:Cytoprotection; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012426:Russia / Q000453:epidemiology; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D018696:Neuroprotective Agents; D014748:Vinca Alkaloids; C013983:vinpocetine